IRD
Opus Genetics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$357.01M
P/E Ratio
—
EPS
$-0.80
Beta
0.52
52W High
$5.81
52W Low
$0.90
50-Day MA
$4.71
200-Day MA
$2.56
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.00
PEG Ratio
—
About Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases that threaten vision. Utilizing advanced research and proprietary gene-editing technologies, Opus aims to address critical unmet medical needs with transformative solutions designed to restore sight. The company's commitment to ocular health, coupled with its robust pipeline supported by ongoing clinical trials and strategic collaborations, positions Opus as a key player in the biotech sector. This innovative approach not only enhances patient outcomes but also presents significant value creation opportunities for investors interested in healthcare advancements.
Fundamentals
| Revenue (TTM) | $14.20M |
| Gross Profit (TTM) | $-16.62M |
| EBITDA | $-38.55M |
| Operating Margin | -296.30% |
| Return on Equity | -242.40% |
| Return on Assets | -55.40% |
| Revenue/Share (TTM) | $0.23 |
| Book Value | $0.22 |
| Price-to-Book | 23.26 |
| Price-to-Sales (TTM) | 25.15 |
| EV/Revenue | 22.05 |
| EV/EBITDA | -2.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -10.20% |
| Shares Outstanding | $71.40M |
| Float | $34.95M |
| % Insiders | 14.70% |
| % Institutions | 37.59% |
Historical Volatility
HV 10-Day
42.60%
HV 20-Day
55.75%
HV 30-Day
60.66%
HV 60-Day
80.29%
HV Rank
30.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.93 target)
1
Strong Buy13
BuyData last updated: 4/29/2026